Clinical Trial

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2021-03-01; most recent amendment 2025-10-15.
Status change: Not Yet Recruiting → Recruiting 2021-08-19
Trial Details
NCT Number NCT04781972
Lead Sponsor Johns Hopkins University
Collaborators: National Institutes of Health (NIH)
Conditions ADHD - Combined Type
Enrollment 30 participants
Start Date 2021-07-27
Primary Completion 2028-11-30 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-16